Recently Completed

Recently Completed

Primary Clinical Trial Publications

WRAP-IT
Tarakji, K.G., Mittal,S., Kennergren,C., Corey,R., Poole,J.E., Schloss,E., Gallastegui,J., Pickett,R.A., Evonich,R., Philippon,F., McComb,J.M., Roark,S.F., et.al., for the WRAP-IT Investigators. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. Published online March 17, 2019. DOI:10.1056/NEJMoa1901111

PRECISION
Nissen, S.E., Yeomans, N.D., Solomon, D.H., Lüscher, T.F., Libby, P., Husni, M.E., Graham, D.Y., Borer, J.S., Wisniewski, L.M., Wolski, K.E. and Wang, Q. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. New England Journal of Medicine, 375 (2016), pp.2519-2529.

GLAGOV
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. The GLAGOV Randomized Clinical Trial.JAMA. Published online November 15, 2016. doi:10.1001/jama.2016.16951

GAUSS-3
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliot M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, for the GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. The GAUSS-3 Randomized Clinical Trial. JAMA. 2016; 315(15):1580-1590. doi:10.1001/jama.2016.3608. Published online April 3, 2016

LIGHT
Nissen, Steven E., Kathy E. Wolski, Lisa Prcela, Thomas Wadden, John B. Buse, George Bakris, Alfonso Perez, and Steven R. Smith. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 315, no. 10 (2016): 990-1004.

ASSURE
Nicholls, Stephen J., Rishi Puri, Kathy Wolski, Christie M. Ballantyne, Philip J. Barter, H. Bryan Brewer, John JP Kastelein et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. American Journal of Cardiovascular Drugs 16, no. 1 (2016): 55-65.

Results from Previous Trials

Results from Previous Trials

Cardiovascular Outcomes

VISTA-16 Varespladib sPLA2 inhibitor 2014 JAMA
dal – Outcomes Dalcetrapib CETP inhibitor 2012 NEJM
TRACER Vorapaxar (PAR-1) Thrombin-Receptor Antagonist 2012 NEJM
CRESCENDO Rimonabant Cannabinoid Receptor Antagonist 2010 LANCET
PPAR Rosiglitazone PPAR Agent 2007 AHJ
CAMELOT Amlodipine (Norvasc®) Anti-Hypertensive 2004 JAMA
GUSTO IV - ACS Abciximab (ReoPro®) GP IIb/IIIa Inhibitor 2001 LANCET
GUSTO IV - ACS Abciximab (ReoPro®) GP IIb/IIIa Inhibitor 2001 LANCET

Antiplatelet

GP IIB/IIIa Inhibitors
CHARISMA Clopidogrel (Plavix®) GP IIb/IIIa Inhibitor 2006 NEJM
FINESSE Abciximab (ReoPro®) GP IIb/IIIa Inhibitor 2008 NEJM
CREDO Clopidogrel (Plavix®) GP IIb/IIIa Inhibitor 2002 JAMA
SYMPHONY Sibrafiban GP IIb/IIIa Inhibitor 2000 LANCET
GUSTO V Abciximab (ReoPro®) GP IIb/IIIa Inhibitor 2002 JAMA
EPIC Eptifibatide (Integrilin®) GP IIb/IIIa Inhibitor 1994 AJC

Thrombin Inhibition

CHOOSE Bivalirudin (Angiomax®) Direct Thrombin Inhibitor 2014 Ann Thorac Surg
REPLACE-2 Bivalirudin (Angiomax®) Direct Thrombin Inhibitor 2006 AHJ
EVOLUTION-ON Bivalirudin (Angiomax®) Direct Thrombin Inhibitor 2006 J Thorac Cardiovasc
EVOLUTION-OFF Bivalirudin (Angiomax®) Direct Thrombin Inhibitor 2006 J Thorac Cardiovasc
CACHET Bivalirudin (Angiomax®) Direct Thrombin Inhibitor 2002 AHJ

Atherosclerosis Progression

AQUARIUS Aliskiren Anti-hypertensive 2003 JAMA
SATURN Rosuvastatin (Crestor®) Statin 2011 NEJM
PERISCOPE Pioglitazone (ACTOS®) TZD 2008 JAMA
STRADIVARIUS Rimonabant Cannabinoid Receptor Antagonist 2008 JAMA
ILLUSTRATE Torcetrapib CETP Inhibitor 2007 NEJM
ASTEROID Rosuvastatin (Crestor®) Statin 2006 JAMA
ACTIVATE CS-505 ACAT Inhibitor 2006 AHJ
REVERSAL Atorvastatin (Lipitor®) Statin 2005 NEJM
CAMELOT/
NORMALISE
Amlodipine (Norvasc®) Calcium Channel Blocker 2004 JAMA
ApoA1 Milano ETC-216 ApoA1 protein 2003 JAMA

Diabetes

STAMPEDE Bariatric Surgery Surgical Therapy 2012 2012

Heart Failure

Ascend HF Nesiritide Recombinant BNP 2011 NEJM

Heart Transplantation

TICTAC Tacrolimus and MMF Immunosuppression 2011 Circ HF
ACCELERATE Data Transparency Initiative

ACCELERATE Data Transparency Initiative

Eli Lilly, in collaboration with the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), will provide access to the individual patient data from the ACCELERATE trial to enable the advancement of cardiovascular research. Proposals will be accepted beginning May 2018. This access is provided in a timely fashion after the primary publication. Researchers must have an approved research proposal to gain access to the trial's patient data.

Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

Most Recent Publication

ADCY9 Genetic Variants and Cardiovascular Outcomes with Evacetrapib in Patients with High Risk
Vascular Disease A Nested Case-Control Study

JAMA Cardiology, published online March 11, 2018

Primary Publication

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

N Engl J Med 2017;376:1933-42